Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 15/20 | 0.38 |
| ▸ | NNMT | P40261 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22707737 | 0.89 | PRMT5 (0.35) | PRMT5WDR77NNMT | |
| SCHEMBL25806907 | 0.88 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL24090742 | 0.88 | PRMT5 (0.35) | PRMT5WDR77NNMT | |
| SCHEMBL21122965 | 0.87 | PRMT5 (0.34) | PRMT5WDR77NNMT | |
| SCHEMBL22485752 | 0.85 | PRMT5 (0.33) | PRMT5WDR77 | |
| SCHEMBL24534261 | 0.85 | PRMT5 (0.33) | PRMT5WDR77NNMT | |
| SCHEMBL24659488 | 0.84 | PRMT5 (0.36) | PRMT5WDR77NNMT | |
| SCHEMBL31123701 | 0.84 | PRMT5 (0.36) | PRMT5WDR77NNMT | |
| SCHEMBL22495013 | 0.83 | PRMT5 (0.37) | PRMT5WDR77NNMT | |
| SCHEMBL24595461 | 0.83 | PRMT5 (0.37) | PRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303612-A1 | Novel Spirobicyclic Analogues | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-28 | — | — | US | disclosed |
| US-11702441-B2 | Spirobicyclic analogues | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702441-B2 | Spirobicyclic analogues | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-20210380627-A1 | Novel Spirobicyclic Analogues | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380627-A1 | Novel Spirobicyclic Analogues | PRMT5, SIRT5, HDAC5 | PRMT5 1/4885WDR77 156/4885NNMT 2016/4885 |
| US-20230303612-A1 | Novel Spirobicyclic Analogues | PRMT5, SIRT5, HDAC5 | PRMT5 1/4885WDR77 156/4885NNMT 2016/4885 |
| US-11702441-B2 | Spirobicyclic analogues | PRMT5, HDAC5, SIRT5 | PRMT5 1/4885WDR77 185/4885NNMT 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.